Analysts expect UroGen Pharma Ltd. to report revenue of 105.55 M for Q4 26, against a range of 99.51 M to 111.58 M. The most recent reported quarter, Q3 26, came in at 89.00 M, a 2.1% beat against the 87.18 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 25.20 M | 24.57 M | 20.25 M | 24.21 M | 27.48 M | 37.84 M | 50.96 M | 72.46 M | 89.00 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 26.60 M | 28.08 M | 25.27 M | 24.21 M | 33.16 M | 39.43 M | 44.76 M | 63.73 M | 92.19 M | 111.58 M | 114.62 M | 142.02 M | 165.42 M | 196.14 M | 134.89 M | 171.32 M | 175.18 M | |||||||||
| Low Estimate | 24.80 M | 25.70 M | 22.78 M | 20.99 M | 30.19 M | 35.64 M | 40.56 M | 54.84 M | 82.16 M | 99.51 M | 107.66 M | 124.86 M | 141.59 M | 171.75 M | 122.95 M | 140.24 M | 164.00 M | |||||||||
| Consensus Estimate | 25.70 M | 26.89 M | 24.02 M | 22.60 M | 31.67 M | 37.54 M | 42.66 M | 59.28 M | 87.18 M | 105.55 M | 111.14 M | 133.44 M | 153.50 M | 183.95 M | 128.92 M | 155.78 M | 169.59 M |
Analysts expect UroGen Pharma Ltd. to report earnings per share of 0.45 for Q4 26, against a range of 0.43 to 0.47. The most recent reported quarter, Q3 26, came in at -0.03, a 128.9% miss against the 0.10 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.55 | -0.80 | -0.92 | -1.05 | -0.69 | -0.54 | -0.47 | -0.28 | -0.03 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | -0.79 | -0.69 | -0.78 | -0.81 | -0.60 | -0.45 | -0.46 | -0.26 | 0.11 | 0.47 | 0.44 | 0.54 | 0.80 | 1.17 | 0.98 | 1.29 | 1.35 | |||||||||
| Low Estimate | -0.95 | -0.83 | -0.88 | -0.97 | -0.70 | -0.51 | -0.52 | -0.32 | 0.09 | 0.43 | 0.38 | 0.50 | 0.70 | 1.01 | 0.86 | 1.11 | 1.21 | |||||||||
| Consensus Estimate | -0.87 | -0.76 | -0.83 | -0.89 | -0.65 | -0.48 | -0.49 | -0.29 | 0.10 | 0.45 | 0.41 | 0.52 | 0.75 | 1.09 | 0.92 | 1.20 | 1.28 |
Pull Wall Street consensus for UroGen Pharma Ltd. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=URGN&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "URGN", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=URGN&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();